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More than 73% of all antimicrobials sold in the world are used in animals
Van Boeckel et al 2017


























• Animal disease is a key constraint:
Billions die each year from preventable & curable disease








Annual mortality of African livestock
( Around half due to preventable or curable disease )
Caveat: a problem of access as well as excess
• Animal disease is a key constraint:
Billions die each year from preventable & curable disease








Ann al mortality of African livestock
















• How much human AMR comes from agriculture?
• What interventions could reduce use in agriculture?
• What are the costs and benefits of these interventions? 
What are the un-intended consequences?                  
Are interventions feasible?
• What effect does the intervention have on human AMR?







































AMR is a One World challenge
• Animal agriculture uses more AM than human health 
does and is rapidly trending up
• Most use and most growth in use is in LMIC
• Dual challenge: access as well as excess
• AMR is not the only externality of disease in LMIC and 
trade-offs need to be examined
• Evidence should under-pin a business case but is 
mostly lacking for LMIC
• Yet there is a strong rationale for One Health as the 
best approach for solving cross-sectoral challenges
Conclusions: 1
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